At Cedars-Sinai Medical Center, clonidine, 0.1 mg PO, was given to patients for premedication before the UROD procedure. Clonidine was subsequently administered in doses of 0.1–1.5 mg via the nasogastric (NG) tube. Acute opioid withdrawal was initiated using naltrexone, 37.5–400 mg, via the NG tube. At Centinela Hospital Medical Center, clonidine was administered incrementally in 0.1-mg IV doses during the UROD procedure. Naltrexone, 300–350 mg via the NG tube, and/or naloxone, 5–15 mg IV, was then administered over 20–30 min to initiate the opioid withdrawal process, followed by either nalmefene (4–12 mg IV), or a combination of nalmefene (4 mg IV) and naloxone (25 mg IV) which was infused over an 8-h period.
Approximately 4 h after the initial withdrawal symptoms ended, patients were administered an additional dose of naloxone, 2–4 mg IV, and then carefully observed for further clinical signs of acute opioid withdrawal. If no withdrawal symptoms were observed, the propofol infusion was discontinued and patients were allowed to awaken from anesthesia. Patients were then transferred to the intensive care unit for continuous electrocardiogram monitoring. Naltrexone, 25 mg PO, was given before discharge and all patients were subsequently administered naltrexone daily for 6 mo.
The occurrence of acute withdrawal symptoms (e.g., hemodynamic changes, nausea, vomiting, and diarrhea) requiring a therapeutic intervention were recorded before discharge from the hospital. These data were analyzed according to the total dose of clonidine administered either PO (at Cedars) or IV (at Centinela). The overall incidences of GI side effects were compared at these two institutions.
Statistical analyses were performed using one-way analysis of variance or Student’s t-test for continuous variables, and when significant differences were determined, a post hoc intergroup comparison was performed using a Newman-Keuls multiple-comparison test. Categorical data were analyzed using χ2 or Fisher’s exact test as appropriate. All tests were two-sided and P values < 0.05 were considered statistically significant.
The clonidine subgroups were comparable with respect to demographic characteristics, dosages of sedative-hypnotics, and opioid antagonist medications administered during the UROD procedure at both medical centers (Tables 1 and 2). However, at Centinela Hospital, the clonidine subgroup receiving the larger total dose of clonidine (>1.0 mg IV) required a smaller dose of propofol than the subgroup receiving the smaller dosage of clonidine (≤1.0 mg IV). The incidences of withdrawal symptoms (e.g., vomiting, diarrhea, and muscle spasms) were not significantly different among the clonidine subgroups at either medical center during the UROD procedure. However, the incidence of diarrhea after the UROD procedure was significantly decreased in patients who received larger dosages of clonidine (>1.0 mg IV or PO) compared with the smaller dosage subgroups at both centers (Tables 1 and 2).
A comparison of the overall incidences of GI side effects at the two medical centers revealed less frequent incidences of vomiting (4% versus 11%, P > 0.05), and diarrhea (1% versus 13%, P < 0.05) during the UROD procedures at Centinela (versus Cedars-Sinai). However, muscle spasms were less frequent during the UROD procedures at Cedars-Sinai compared with Centinela (52% versus 75%, P < 0.05). After the UROD procedure, the incidences of nausea (39% versus 31%, P > 0.05) and vomiting (35% versus 26%, P > 0.05) were similar at the two medical centers. However, the incidence of diarrhea was significantly reduced after the UROD procedure at Centinela compared with Cedars-Sinai (11% versus 35%, P < 0.05).
The acute withdrawal symptoms associated with the UROD procedure can lead to dehydration and electrolyte disturbances, as well as patient discomfort. Clonidine, an α2-adrenergic agonist, has been reported to be effective in suppressing symptoms of opioid withdrawal (12–16). There are no clinical studies evaluating the antidiarrheal activity of clonidine during and after UROD procedures. In animal studies, clonidine has been reported to prevent naloxone-precipitated morphine withdrawal symptoms in a dose-dependent manner (5,10,11). In a rat study (10), diarrhea occurred in all animals undergoing morphine withdrawal without clonidine. However, clonidine, 0.1 mg/kg IV, decreased the incidence of diarrhea by 50%, and a 0.3-mg/kg IV dose effectively prevented diarrhea in this animal model. In our retrospective clinical assessment, the incidence of diarrhea seemed to be decreased with increasing dosages of clonidine when given either PO or IV to patients undergoing UROD procedures. A comparison of the overall antidiarrheal efficacy of clonidine suggested that the IV route of administration was more effective than giving the drug PO.
Clonidine has been used to treat patients with intractable diarrhea secondary to diabetes, cholera, or small bowel transplantation (6–8). Previous animal and human studies have suggested that the antidiarrheal properties of clonidine are largely attributed to effects on fluid absorption in the small bowel and intestinal motility (9,17–20). Although the site of action of clonidine in preventing diarrhea associated with opiate withdrawal is unclear (5), some authors have suggested that withdrawal-induced diarrhea may be mediated through α2-adrenoceptors located on intestinal smooth muscle (10,11).
During the UROD procedure, clonidine was administered primarily to attenuate the systemic effects associated with opiate withdrawal (21). Most of the published studies used clonidine, 5–6 μg/kg PO, to control opiate withdrawal symptoms (11,12). However, larger doses of clonidine (e.g., >10 μg/kg) have been used in patients undergoing opiate detoxification without significant side effects (14). In this retrospective study, the dosage of clonidine used during the UROD procedures varied from 2 to 30 μg/kg. Although two patients in our study population experienced transient bradycardia after large doses of clonidine (>1 mg IV), this side effect did not require anticholinergic treatment. The use of larger IV doses of clonidine not only decreased the incidence of diarrhea, but also produced a reduction in the propofol dosage requirement during the UROD procedure.
Our current analysis can be criticized because: 1) this was a retrospective chart review, 2) there was no “placebo” control group receiving no clonidine because of ethical concerns, and 3) the dosages of adjunctive drugs were not standardized (e.g., opioid antagonist). In the future, a prospective, randomized, double-blinded dose-ranging study should be performed to more precisely quantify the antidiarrheal effect of clonidine in patients undergoing UROD procedures.
In conclusion, clonidine seems to be beneficial in reducing diarrhea associated with UROD procedures. In addition, the use of larger doses of IV clonidine can also produce a dose-dependent propofol-sparing effect.
1. O’Conner PG, Kosten TR. Rapid and ultrarapid detoxification techniques. JAMA 1998; 279: 229–34.
2. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet 1999; 353: 221–6.
3. Lorenzi P, Marsili M, Boncinelli S, et al. Searching for a general anaesthesia protocol for rapid detoxification from opioids. Eur J Anaesthesiol 1999; 16: 719–27.
4. Spanagel R. Is there a pharmacological basis for therapy with rapid opioid detoxification? Lancet 1999; 354: 2017–8.
5. Nakaki T, Chang PC, Tokunaga Y, et al. Alpha 2-adrenoceptors modulating diarrhea in morphine-dependent rats. J Pharm Pharmacol 1981; 33: 397–9.
6. Migliore A, Barone C, Manna R, et al. Diabetic diarrhea and clonidine. Ann Intern Med 1988; 109: 170–1.
7. Rabbani GH, Butler T, Patte D, et al. Clinical trial of clonidine hydrochloride as an antisecretory agent in cholera. Gastroenterology 1989; 97: 321–5.
8. Rovera G, Furukawa H, Reyes J, et al. The use of clonidine for the treatment of high intestinal output following small bowel transplantation. Transplant Proc 1997; 29: 1853–4.
9. Schiller LR, Santa Ana CA, Morawski SG, et al. Studies of the anti-diarrheal action of clonidine: effects on motility and intestinal absorption. Gastroenterology 1985; 89: 982–8.
10. Distefano PS, Brown OM. Biochemical correlates of morphine withdrawal. II. Effects of clonidine. J Pharmacol Exp Ther 1985; 233: 339–44.
11. Thollander M, Hellstrom PM, Svensson TH. Suppression of small intestinal motility and morphine withdrawal diarrhea by clonidine: peripheral site of action. Acta Physiol Scand 1989; 137: 385–92.
12. Gold MS, Redmond DE, Kleber HD. Clonidine in opiate withdrawal. Lancet 1978; 1: 929–30.
13. Gold MS, Redmond DE, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 1978; 2: 599–602.
14. Gold MS, Pottash AC, Sweeney DR, et al. Opiate withdrawal using clonidine: a safe, effective, and rapid nonopiate treatment. JAMA 1980; 243: 343–6.
15. Riordan CE, Kleber HD. Rapid opiate detoxification with clonidine and naloxone. Lancet 1980; 1: 1079–80.
16. Charney DS, Riordan CE, Kleber HD, et al. Clonidine and naltrexone: a safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy. Arch Gen Psychiatry 1982; 39: 1327–32.
17. Rubinoff MJ, Piccione PR, Holt PR. Clonidine prolongs human small intestine transit time: use of the lactulose-breath hydrogen test. Am J Gastroenterol 1989; 84: 372–4.
18. Doherty NS, Hancock AA. Role of alpha-2 adrenergic receptors in the control of diarrhea and intestinal motility. J Pharmacol Exp Ther 1983; 225: 269–74.
19. Chang EB, Field M, Miller FJ. Alpha 2-adrenergic receptor regulation of ion transport in rabbit ileum. Am J Physiol 1982; 242: G237–42.
20. Nadaki T, Nakadate T, Yamamoto S, et al. Alpha 2-adrenergic inhibition of intestinal secretion induced by prostaglandin E1
, vasoactive intestinal peptide and dibutyryl cyclic AMP in rat jejunum. J Pharmacol Exp Ther 1982; 220: 637–41.
© 2003 International Anesthesia Research Society
21. Gold CG, Cullen DJ, Gonzales S, et al. Rapid opioid detoxification during general anesthesia: a review of 20 patients. Anesthesiology 1999; 91: 1639–47.